# CoviCept Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/covicept-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Total disclosed funding: $2.3M
- Latest round: Seed (Jan 19, 2021)
- Investors on record: 1

## About

Founded in 2020 by co-founders Sam Tsimikas, Philip Gordts, and Jeffrey Esko and based in California, US, CoviCept Therapeutics, Inc., producer of a small molecule intended to restrain the spread of RNA viruses, including SARS-Cov-2. In January 2021, CoviCept Therapeutics, Inc. raised USD 2.3 million in seed funding from investor Forbion.

CoviCept Therapeutics, Inc offers a small molecule drug designed to interfere with a host cell protein that is essential for the replication of RNA viruses. By targeting a host factor rather than the virus directly, the approach reduce the resistance developing through viral mutation. The compound has demonstrated the ability to inhibit SARS-CoV-2 replication in preclinical animal models and has shown activity against other RNA viruses, including zika and dengue. The compound has also completed Phase 1 clinical trials. In October 2021, CoviCept initiated a Phase 2 clinical trial of SARS-CoV-2 and other RNA viruses.

## Funding rounds

- Seed, Jan 19, 2021, $2.3M — Forbion

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed